Sixth Wave Innovations (SIXW / AHUH)

Atlan hat am 23.01.2021 10:19 geschrieben:

Quote

Es gab letztes Jahr diesen Peak > 1 $ , hatte mich da auch gewundert was da los war. Ich denke da waren wahrscheinlich Börsenbriefe am pushen wie es bei solchen Werten oft vorkommt. Da wird im voraus gekauft dann gepusht und dann wieder fallen gelassen. In der Regel sind da die betroffenen Firmen nicht mal involviert , einfach Spielball.

Das gleiche Spiel habe ich bei meiner Recherche von EXRO gesehen. Die wurden in frühren Jahren von deutschen Börsenbriefen auch so manipuliert. Die Kunst besteht nun herauszufinden ist die Firma nur Spielball oder involviert. Bei EXRO ist die Sachlage klar, hier denke ich wir sind auch auf dem richtigen Weg , aber nur meine Meinung.

Aber danke für den Beitrag, kritische Fragen sind immer hilfreich ...

Das ist bei Core One Labs in den letzten Wochen auch mehrmals passiert. Die ist auch dort gelistet.

News

Sixth Wave Announces Extension of SARS-CoV-2 Research Agreement with UofA and Li Ka Shing Institute of Virology - Newsfile

18-Mar-2021 14:04:54

Halifax, Nova Scotia--(Newsfile Corp. - March 18, 2021) - Sixth Wave Innovations Inc. (CSE: SIXW) (OTCQB: ATURF) (FSE: AHUH) ("Sixth Wave", "SIXW" or the "Company") is pleased to announce the extension of its research and development relationship with the University of Alberta ("UofA") and the Li Ka Shing Institute of Virology ("LKS"), pursuant to the development of the Company's Accelerated Molecular Imprinted Polymers ("AMIPs™") technology for the detection of the virus that causes COVID-19 (the "Virus").

As previously announced, SIXW established a Service Agreement with UofA and LKS to facilitate the development of AMIPs™ (the "Service Agreement"). The original contract provided for the continuation of the work through April 30, 2021 and included provisions for the imprinting of the Virus and early-stage validation testing. Please see SIXW Press Release dated November 23, 2020 for more information on AMIPs and the UofA/LKS Service Agreement.

Announcement of Extension of Service Agreement

Based on the success of the collaboration thus far, SIXW and UofA have now executed a no-cost extension of the Service Agreement. The extension provides for a continuity of our development work at the UofA/LKS through April, 30 2022, unless otherwise extended by mutual consent. The extension has no impact on the ownership of associated intellectual property owned solely by SIXW for AMIPs.

The extension of the Services Agreement will enable continued laboratory work and analytics to establish a definitive version of a polymerized molecular imprint of the Virus via AMIPs technology (the "Definitive Imprint"). Once AMIPs™ achieves clinical efficacy targets, the Definitive Imprint will then form the basis of AMIPs™ virus detection products. The AMIPs™ polymer is expected to be useful in the manufacture of an extensive array of rapid, durable, and versatile virus detection tools, including handheld devices, wearables, and airborne detection tools (see SIXW Press Release dated April 3, 2020 (https://www.newsfilecorp.com/redirect/aGvQuqvKP), for additional details of the proposed practical uses of AMIPs™).

The extended Research Agreement will additionally include optimization work designed to further authenticate and enhance the AMIPs design ("Optimization Testing"), as discussed below.

"This agreement extension is a result of the rapid early success in the development of AMIPs, the strong relationship developed between the organizations and continued support of the key researchers at the UofA," said Dr. Jon Gluckman, President and CEO of Sixth Wave. "Perhaps most remarkable is the short time frame in which the research team has delivered the COVID-19 AMIPs™ prototype ready for optimization. The entire process, from initial wet chemistry to the sensor prototypes now undergoing optimization, has been accomplished in approximately 90 days. This rapid turnaround is a testament to the responsiveness and versatility of AMIPs as a means of identifying novel, complex and ever-mutating pathogens. We're privileged to have the UofA/LKS on our team and look forward to continued success."

Announcement of Completion of Contract with NS COVID-19 Response Council

As previously reported, SIXW recently produced a first-generation molecular imprint of the Virus (the "Imprint"), thereafter commencing a series of validation tests to quantify the accuracy of the imprinting process (the "Validation Testing"). Using the preliminary results, improvements in the production and measurement processes were made toward generation of AMIPs™ which achieved definitive and quantifiable detection of COVID-19 virus as steps toward the Definitive Imprint (see SIXW press release dated March 9, 2021).

Initial Validation Testing is now considered complete and has successfully demonstrated the efficacy of the AMIPs prototype using a combination of Quartz Crystal Microbalance ("QCM") and Atomic Force Microscopy ("AFM") at the UofA laboratory in Edmonton. Achieving this goal officially completes the proof of concept and the Company's primary obligations under the contribution agreement awarded to SIXW by the Nova Scotia COVID-19 Response Council (the "Contribution Agreement" and the "Council", respectively).

Sixth Wave expresses its gratitude again to the Council for their support and will be briefing the Council as soon as schedules permit to officially complete the Agreement and determine if the Company's development path warrants additional participation. Please see SIXW press release dated October 27, 2020 for more information on the Contribution Agreement and associated requirements.

Forthcoming Optimization Testing

The forthcoming work at UofA which is ongoing and pursuant to the extension of the Research Agreement will focus on the optimization of the AMIPs prototype, within the following general categories of research: 1. Variant Testing - Testing and validating the current AMIPs™ detection capability for the major known variants of the COVID-19 virus. 1. Sensitivity and Selectivity Testing - Initial validation was successfully demonstrated using a combination of QCM and AFM technologies, as discussed in prior announcements. The development team is now moving toward more sensitive measurement techniques including Quartz Crystal Microbalance with Dissipation Monitoring ("QCM-D") based on ring-down technique. QCM-D will allow more accurate measurement of detection limits and flexibility in evaluation of interferents that will be present in real-world samples. This effort will ensure that the Definitive Imprint will meet both detection limits and reliability at clinically acceptable levels. 1. Colorimetric Testing - Testing early-stage colorimetric chemistry, to provide the basis for non-electronic or fieldable electronic detection capabilities. Colorimetric detection is useful for several of the productization pathways that the Company intends to pursue including AMIPs™ based ELISA tests, lateral flow tests, and the SmartMask™. Once perfected, color changes can be implemented such that positive detections can be seen visually and can also be manipulated to change bar codes or Quick Response codes ("QR") allowing for machine reading of results and ultimately integration with contact/virus outbreak tracing. Such automation will allow anyone to read their test results individually or as part of entry to schools, work recreational activities, etc. and maintain privacy while providing health experts with needed data on transmission and outbreak epicenters. 1. Development of Imprint Stamp - A major advancement in the production of AMIPs will be development of the re-usable imprint stamp. The stamp provides the capability for mass production of the AMIPs polymer without continued access and use of the target virus. Test work at the UofA laboratories is progressing under the direction of Sixth Wave Senior Scientist Dr. Garrett Kraft, in cooperation with Dr. Michael J. Serpe (UofA Department of Chemistry) and Dr. Michael Joyce (UofA Department of Medical Microbiology). The relationship with UofA allows for access to the Virus and other pathogens, as well as access to a variety of advanced analytical equipment needed for this development.

As previously reported, SIXW has filed two patents regarding the AMIPs™ technology and its application to specific products that can utilize AMIPs™. The Company is not making any express or implied claims that its current AMIPs™ product has the ability to eliminate, cure, contain, or detect, at a commercial level, COVID-19 (or SARS-2 coronavirus) at this time.

For more information on the AMIPs™ and associated molecular imprinting technology, please visit: https://www.amips.com.

About Sixth Wave

Sixth Wave is a nanotechnology company with patented technologies that focus on extraction and detection of target substances at the molecular level using highly specialized Molecularly Imprinted Polymers (MIPs). The Company is in the process of a commercial rollout of its Affinity™ cannabinoid purification system, as well as, IXOS®, a line of extraction polymers for the gold mining industry. The Company is in the development stages of a rapid diagnostic test for viruses under the Accelerated MIPs (AMIPs™) label.

Sixth Wave can design, develop and commercialize MIP solutions across a broad spectrum of industries. The company is focused on nanotechnology architectures that are highly relevant for the detection and separation of viruses, biogenic amines, and other pathogens, for which the Company has products at various stages of development.

For more information about Sixth Wave, please visit our web site at: www.sixthwave.com.

ON BEHALF OF THE BOARD OF DIRECTORS

"Jonathan Gluckman"
Jonathan Gluckman, Ph.D., President & CEO

Zwischen den Zeilen

Wer zwischen den Zeilen lesen kann, der weiss, dass das sehr gute News sind.

Based on the success of the collaboration thus far, SIXW and UofA have now executed a no-cost extension of the Service Agreement.

Eine no-cost extension dürfte nur dann abgeschlossen werden, wenn beide Seiten von diesem Projekt überzeugt sind. Der UofA geht es mit der Entwicklung von AMIPS nicht um monetäre Interessen (Patent und Linzenzrechte sind ausschliesslich bei SIXW) sondern um akademische Anerkennung. Das Forschungsteam könnte hier bei einer potenziell revolutionären Testmethode mitwirken, klar dass sie sich hier ein Teil der Lorbeeren einheimsen möchten. Ich intepretiere daraus, dass die Entwicklung weit fortgeschritten ist und wir hier bald mit bahnbrechenden News zu AMIPS rechnen können.

Wow, Order Book Level 3 Daten sehen extrem stark aus. Viele Aufträge und ordentliches Volumen auf der Geld Seite. Bis .49 praktisch nichts Brief gestellt.

Nochmals kurz zur Erinnerung mit wem hier SIXW zusammenarbeitet. Das Li ka Shing Institut wird unter anderem auch von der Bill and Melinda Gates Stiftung unterstützt. Wir sprechen hier von Top Forschern und nicht von einer Feld, Wald und Wiesen Fakultät.

Das Li Ka Shing Institute of Virology (LKSIoV) vereint ein Konsortium von weltweit anerkannten Forschern, um wissenschaftliche Fortschritte zu fördern, die darauf abzielen, unser Verständnis von Viren und anderen ausgewählten Krankheitserregern, ihrer jeweiligen Krankheitspathogenese und der Immunantwort des Wirts auf solche Infektionen zu erweitern. Das Institut stützt sich auf international anerkannte Expertise in Virologie, Immunologie und anderen Bereichen menschlicher Krankheiten sowie auf eine Infrastruktur mit globalen Verbindungen zu Partnern wie den U.S. National Institutes of Health, der Bill and Melinda Gates Foundation, den Canadian Institutes of Health Research (CIHR) und anderen.

Durch das Li Ka Shing Applied Virology Institute (LKSAVI) unterstützt das LKSIoV weiterhin Entdeckungen im Bereich Impfstoffe, Behandlungen und diagnostische Tests für virale und ausgewählte andere Krankheiten, die den Menschen betreffen. Das Institut ist führend in der Nutzung von künstlicher Intelligenz (KI) für computergestütztes Wirkstoffdesign.

Die außergewöhnliche virologische und immunologische Forschung an der University of Alberta war einer der vielen ausschlaggebenden Gründe für die Gründung des Li Ka Shing Institute of Virology am 23. April 2010. Seine Gründung wäre nicht möglich gewesen ohne die kombinierten Spenden von 52,5 Millionen Dollar von der Regierung von Alberta und 25 Millionen Dollar von der Li Ka Shing (Kanada) Stiftung, der grössten Spende in der Geschichte der Universität von Alberta.

Quelle: https://www.ualberta.ca/li-ka-…rology/about/mandate.html

Was ich zusätzlich noch herausstreichen möchte, dass die Vereinbarung bis im April 2022 (!) läuft. Wie ich schon mehrfach erwähnt habe wird die Anwendung von AMIPS nicht durch SARS-CoV-2 limitiert sondern kann auch für eine Reihe weiterer Viralerbedrohungen eingesetzt werden. Sobald die Entwicklung von AMIPS für Covid-19 abgeschlossen ist, werden sich die Forscher wohl weiteren Virusstämmen widmen.

Besten Dank für diese Infos und Betrachtungen, Tony aka Tony001

Bitte gern geschehen, schön liest noch jemand mit hier.

(SIXW / AHUH) Volumen

Hallo zusammen

Der Kurs wird in Canada gemacht und ich konnte jedoch nur AHUH in Euro kaufen.

Wenn ich mir das heutige Handelsvolumen betrachte steht da nicht wirklich viel. Stand immer noch 08.16h Null Volumen

Volumen war Heute tatsächlich sehr bescheiden. Bis jetzt war Liquidität in Kanada immer in Ordnung aber auch dort wurden heute nur 25k gehandelt.

NEWS - und jetzt ab zum Mond?

Wieder hervorragende News. Zündet nun endlich die Rakete?!

Sixth Wave Demonstrates Colorimetric Detection
of SARS-CoV-2 utilizing AMIPs™

Halifax, Nova Scotia – (April 14, 2021) – Sixth Wave Innovations Inc. (CSE:SIXW) (OTCQB:ATURF) (FSE:AHUH) (“Sixth Wave”, “SIXW” or the “Company”) is pleased to announce that it has successfully demonstrated colorimetric detection of SARS-CoV-2, the virus that causes COVID-19 (the “Virus”) utilizing the Company’s patent pending Accelerated Molecular Imprinted Polymers (“AMIPs™”) technology.

Colorimetric detection is a method of identifying the presence of a target substance within a test sample by means of a color reagent. When successfully applied, the activation of the reagent indicates the presence of the target substance.

The demonstration, performed by way of a simulated synthetic enzyme-linked immunosorbent assay (“ELISA”) test, is represented by the following microscopic images:

Fig 1: Colorimetric Response of AMIPsTM to SARS-CoV-2 Virus

[Blocked Image: https://sixthwave.com/wp-conte…021/04/AMIPs-1030x439.png]

The image on the left shows the AMIPs™ polymer having been exposed to SARS-CoV-2, with the fluorescent highlights indicating the presence of the Virus. The image on the right shows the AMIPs™ polymer having been exposed to a non-infected sample. (Images produced using Olympus spinning disk Confocal microscope at ONLY 20x magnification)

The Company intends to build on this initial validation toward the development of a colorimetric sensor for a potentially wide range of rapid Virus detection devices using AMIPs™. The spectrum of prospective products includes SIXW’s SmartMask™ (see SIXW Press Release dated May 15, 2020), in addition to, airborne sensors, breathalyzers, synthetic ELISA-like tests, cartridge/lateral flow tests, and others.

“Colorimetric detection is an important development for AMIPs™ technology,” said Dr. Jon Gluckman, President and CEO of Sixth Wave. “As previously disclosed, the AMIPs™ polymer captures the COVID-19 virus, as intended, and is now supported by three independent analytical methods. Two primary objectives of any rapid diagnostic tool are definitive results and ease of interpretation. Colorimetric Sensors can deliver on both fronts and this is a material step in that direction.”

“As previously disclosed, AMIPs™ are designed to be resistant to loss in efficacy due to virus mutation and emergence of variants which may change the specific antibody/antigen reaction but have yet to create gross changes to the size and shape of the Virus. AMIPs™ also has the potential to identify multiple types of viruses (coronavirus, influenza virus, rhinovirus etc.) in a single platform,” said Garrett Kraft, Sixth Wave’s Lead AMIPs™ researcher. “The confirmation of colorimetric detection from this test opens the possibility of deploying a palette of colors to identify multiple viruses in a single pass such as influenza AND COVID-19 with different colors for each. This potential for independent color coding is perhaps the most promising aspect of AMIPs™ as a versatile diagnostic tool. Ideally, our end AMIPs™ product will be a ‘Swiss Army Knife’ of sorts, performing multiple diagnostic tests in a single application.”

The Company is not making any express or implied claims that its product has the ability to eliminate, cure, contain, or detect, at a commercial level, COVID-19 (or SARS-2 coronavirus) at this time.

Details on Initial Colorimetric Detection Test Work

The test performed was designed to simulate an ELISA test but using AMIPs™. ELISA tests are a go-to detection technology employed extensively in the health services arena. In its most basic form, ELISA starts by isolating a target pathogen such as SARS-CoV-2 (the “Antigen”). The Antigen is immobilized on a solid surface known as a microplate. An antibody targeted for the pathogen (the “Antibody”), will have an associated enzyme (the “Reporter Enzyme”). When the Antibody binds to the immobilized Antigen the Reporter Enzyme is chemically bound to the virus. The sample is rinsed to remove unbound Reporter Enzyme, only leaving the Reporter Enzymes that are bound to the virus. An indicator solution is incubated with the sample and any Reporter Enzymes in the sample will catalyze a chemical reaction, thus inducing a color change. From the color change, the researcher can infer that binding between the Antigen and Antibody has occurred, and that the target pathogen (the Virus) is present. The foregoing process produces the colorimetric response that represents detection of a virus.

Using the foregoing ELISA methodology as a starting point, Sixth Wave researchers modified the technique to accommodate the unique features of AMIPs™ molecular imprinting technology. As with all immunoassay tests, ELISA tests require the use of an Antibody-Antigen binding for detection. AMIPs™ replaces the Antibody with a molecular imprint of the whole Virus, and replaces the Antibody with the AMIPs™ imprinted polymer. A chemically engineered binding mechanism built into the polymer, provides a force of attraction between the Virus and the AMIPs™ eliminating any need of biological material including Antibodies. The Reporter Enzymes in classic ELISA tests help amplify the color response making detection easier and, while it was not needed in this test, may be useful in certain AMIPs™ products. The value of AMIPs™ in this regard is multifold:

• Simplicity & Flexibility – AMIPs™ test does not require the use of Antibodies, which are biological materials subject to supply chain complexity (must be grown in host animals subsequently sacrificed, stored/transported under refrigeration/freezing), degradation from environmental factors (heat, sun, etc.) which limit how they can be deployed, and as of yet have not been easily configured to detect multiple viruses in a single test. In an ELISA type configuration AMIPs™ can provide the same performance and form factor clinical laboratory workers are accustom to while providing a robust, reliable, and lower cost product.
• Robust Detection Capability – AMIPs™ should be more robust in its ability to detect variants of COVID-19. This is because the mechanism used to capture and immobilize the Virus is not keyed to a specific Antigen-Antibody relationship. The Antigen-Antibody relationship is based on antibody interactions with a small section of a viral protein. This interaction is highly specific but constantly challenged with an ever-changing set of variables due to natural mutation, with significant changes in the Antigen (virus) making it resistant or “invisible” to existing Antibodies.
• Variants – As already well documented for many viruses (i.e COVID-19 and influenza) several of the variants of COVID-19 are more transmittable and more deadly (including the United Kingdom, South African, and Brazilian variants) due to such mutation. Immunoassay tests as a class which rely on Antibodies for immobilization and detection of the Virus are ultimately subject to the same inherent potential to miss both known and emergent variants in the same way the human body’s immunity can be bypassed and as such may be much more susceptible to false negative results than the more wholistic capture and detection methods implemented in AMIPs™.
• Additional Validation – The AMIPs test provides additional validation that the AMIPs™ polymer works. The latter being in addition to the QCM/QCM-D and AFM confirmations previously announced.

The research results obtained directly compared the prototype AMIPs™ polymer against infected and non-infected cell cultures to ensure detection was based on the presence of the virus and not binding of any other components of the cellular milieu or non-specific interactions between the polymer and the fluorescent dye. Detection was observed using an Olympus spinning disk Confocal microscope. In lay terms, two AMIP™ sensors were used in the experiment. One sensor was exposed to an infected cell culture solution and the other sensor was exposed to a non-infected cell culture solution. Both sensors were then washed to remove unbound material. The AMIPs™ were then exposed to the off-the-shelf florescent dye in accordance with the manufacturer’s standard protocols. The dye has chemical functionalities that will react non-specifically with most proteins. The dye solution was then washed off and the sensors were imaged under the microscope at 20x magnification. The results were overwhelmingly clear – AMIPs™ showed detection. No florescent response was observed from the sensor exposed to non-infected cell culture solution. The results demonstrate that the AMIPs polymer selectively binds the SARS-CoV-2 virus and that there are no non-specific interactions between the AMIP polymer and common cellular components or interferants.

Completion of Briefing to Nova Scotia COVID-19 Response Council

The Company is also pleased to report that it has successfully completed its final briefing to the Nova Scotia COVID-19 Response Council. This was well received and represents the final deliverable under the awarded Contribution Agreement previously announced on October 27, 2020 (the “Council” and the “Contribution Agreement ”, respectively).

For more information on the AMIPs™ and associated molecular imprinting technology, please visit: https://www.amips.com

About Sixth Wave

Sixth Wave is a nanotechnology company with patented technologies that focus on extraction and detection of target substances at the molecular level using highly specialized Molecularly Imprinted Polymers (MIPs). The Company is in the process of a commercial rollout of its Affinity™ cannabinoid purification system, as well as, IXOS®, a line of extraction polymers for the gold mining industry. The Company is in the development stages of a rapid diagnostic test for viruses under the Accelerated MIPs (AMIPs™) label.

Sixth Wave can design, develop and commercialize MIP solutions across a broad spectrum of industries. The company is focused on nanotechnology architectures that are highly relevant for the detection and separation of viruses, biogenic amines, and other pathogens, for which the Company has products at various stages of development.

For more information about Sixth Wave, please visit our web site at: http://www.sixthwave.com

ON BEHALF OF THE BOARD OF DIRECTORS

“Jonathan Gluckman”
Jonathan Gluckman, Ph.D., President & CEO

Quo vadis?

Hmmh, irgendwie so ruhig geworden rund um die Aktie, und der Kurs bröckelt langsam aber sicher ab...

Was ist in den nächsten Wochen und Monaten konkret zu erwarten? Hat da jemand Infos?

Tony - any idea about the future of this stock? Thanks mate

Trotz guten Resultaten von AMIPS ist es in den letzten Wochen auffällig ruhig geworden um SIXW. Hinter den Kulissen scheint aber einiges zu gehen und ich vermute, dass wir in kürze mehr darüber erfahren werden. In der Vergangenheit hatte John Gluckman die positiven Ergebnisse von AMIPS immer wieder zum Anlass genommen, um kräftig die Werbetrommel zu rühren und fleissig Interviews zu geben. Im Moment ist da viel Zurückhaltung zu spüren. Ich gehe davon aus, dass zuerst noch abgewartet wird, bis das fehlende Puzzle-Stück hier ist. Zulassungsantrag? Staatliches Funding? Kooperation mit Big Pharma? I don't know....

Ich habe meine Position leicht reduziert, bin aber immer noch mit einem schönen Engagement dabei...

Autsch - heute minus 18%. Was ist da los?!